Goldman Sachs
June 12, 2026
Americas Healthcare Biotechnology Script Tracker
Weekly UpdateEquitiesHealth Care
This report tracks weekly prescription trends for key biotech products including Amvuttra, Leqembi, Yeztugo, Journavx, Spikevax, and Uplizna. Data is provided as an aid to assessing 2Q sales tracking against consensus expectations.
Key Takeaways
- 1.ALNY's Amvuttra showed strong script performance (+148%/+138% WoW), benefiting from US market growth and prescriber base expansion.
- 2.BIIB's Leqembi saw a 17% WoW decline in script volume, with management looking toward 2027 for acceleration via subcutaneous maintenance approval.
- 3.VRTX's Journavx for acute pain grew 20% WoW, with management anticipating revenue growth to outpace prescription growth through YE26.
Table of Contents
- Disclosure Appendix
- Reg AC
- GS Factor Profile
- M&A Rank
- Quantum
- Disclosures
- Regulatory disclosures
- Ratings, coverage universe and related definitions
- Global product; distributing entities
- General disclosures
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Salveen RichterShrunatra MishraElizabeth Webster, Ph.D.Matt Dellatorre, Ph.D.Tommie ReerinkLydia ErdmanMark Aleynick
Securities
ALNYBIIBGILDVRTXMRNAAMGN
Themes
Biotechnology commercializationHigh-frequency sales monitoring
Regions
North AmericaUnited States